# Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

> **NCT01215565** · PHASE2 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 4 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Fibrolamellar Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sutent

## Key facts

- **NCT ID:** NCT01215565
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-05
- **Final completion:** 2012-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** lack of inclusion
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215565, "Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01215565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*